Ventum Cap Mkts Weighs in on Sernova Corp.’s FY2025 Earnings (TSE:SVA)

Sernova Corp. (TSE:SVA) – Equities research analysts at Ventum Cap Mkts issued their FY2025 earnings per share estimates for shares of Sernova in a research note issued to investors on Tuesday, September 17th. Ventum Cap Mkts analyst S. Quenneville expects that the company will post earnings per share of ($0.10) for the year. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.

Sernova (TSE:SVA) last posted its quarterly earnings results on Monday, September 16th. The company reported C($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.01.

SVA has been the topic of several other reports. Leede Financial reduced their price target on Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating on the stock in a research report on Friday, September 13th. Ventum Financial lowered their price objective on Sernova from C$3.00 to C$2.50 and set a “buy” rating for the company in a report on Friday, September 13th.

Sernova Stock Performance

TSE:SVA opened at C$0.26 on Thursday. The firm’s fifty day simple moving average is C$0.26 and its 200 day simple moving average is C$0.36. The firm has a market capitalization of C$82.72 million, a price-to-earnings ratio of -1.96 and a beta of 1.38. Sernova has a twelve month low of C$0.20 and a twelve month high of C$0.83. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55.

Insider Activity at Sernova

In other news, Director Steven Sangha sold 930,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders purchased 379,600 shares of company stock worth $97,671 in the last 90 days. 12.98% of the stock is currently owned by company insiders.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.